Valeant (VRX) August weekly volatility elevated as shares up in premarket on Q2 and outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/8/2026
- S&P 500, Dow set to open lower as Gulf tensions send oil to over six-week high
- Brent crude hits six-week high near $97 as Houthi strike targets Saudi Aramco
- Energy stocks rise premarket as oil prices climb on Middle East supply fears
- Novartis shares plunge 10% as failed drug trial clouds growth outlook
- After an 18% summer selloff in chip stocks, Citi asks what comes next
- Citi initiates UiPath coverage with Buy rating and $23 target
- Trump says Canada's Bombardier must build jets in US or lose market access
- European shares subdued as surging crude sharpens focus on ECB rate path
- Alibaba (BABA) PT Lowered to $165 at Bernstein SocGen Group
- WestPark Capital Starts Akebia Therapeutics (AKBA) at Buy
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
RBC Affirms Valeant (VRX) at 'Sector Perform'; Q2 Slightly Below Views, Walgreens Derm co-Pay Shows Improvement
August 9, 2016 9:32 AM EDTRBC affirms Valeant (NYSE: VRX) Sector Perform with a price target of $31 following Q2 results on Tuesday.
Analyst Douglas Miehm offered the following quick commentary ahead of the company's conference call:
Total revenues in Q2/16 were $2.42B vs. our forecast of $2.47B, and consensus of $2.47B (FactSet,15 analysts, $2.30-2.66B range). Relative to our forecasts, the Derm, GI, and Neuro/Other segments came in below our expectations, and the Emerging... More
